Gufic Biosciences enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


4,249	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
62.2	62.2	15.7	1.1	28.6
0.0	0.0	0.0	—	—
385	385	310	317	191
4,573	—	—	—	—
323	323	295	316	162
₹455.96	—	—	—	—

1,050	1,050	911	850	538
36.7%	36.7%	34.1%	37.3%	35.4%
0.08×	—	—	—	—

4.66×	—	—	—	—
27.77×	—	—	—	—
34.17×	—	—	—	—
331.66×	—	—	—	—
981	944	820	807	—
165	151	135	146	—
134	121	114	129	—
—	45.0	123	−7.5	−26.6
13.8	13.8	47.0	−120	−26.6
—	5.3	41.6	−123	—
—	31.2	75.5	113	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

GUFICBIO₹423.75

Gufic Biosciences Limited

· Pharma & Health

₹ CrorePeersRPGLIFE UNICHEMLAB GUJTHEM ORCHPHARMA SMSPHARMA INDSWFTLAB FDC IOLCPMcap ₹4,249 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	4,249.5
- Cash, Equiv & ST Investments	28.6	1.1	15.7	62.2	62.2
+ Minority Interest	—	—	0.0	0.0	0.0
+ Total Debt	190.7	317.0	310.4	385.2	385.2
Enterprise Value	—	—	—	—	4,572.5
Net Debt (memo)	162.1	315.9	294.7	323.0	323.0
EV per Share	—	—	—	—	455.96

Total Capital	538.5	849.6	911.5	1,050.1	1,050.1
Total Debt/Total Capital	35.41	37.32	34.05	36.68	36.68
Total Debt/EV	—	—	—	—	0.08

EV/Sales	—	—	—	—	4.66
EV/EBITDA	—	—	—	—	27.77
EV/EBIT	—	—	—	—	34.17
EV/Free Cash Flow	—	—	—	—	331.66
Reference Items — Trailing FY Values
Sales	—	806.7	819.8	944.0	981.1
EBITDA	—	145.9	134.7	151.3	164.6
EBIT	—	128.9	113.6	120.5	133.8
Operating Cash Flow	-26.6	-7.5	122.6	45.0	—
Free Cash Flow	-26.6	-120.2	47.0	13.8	13.8
FCFF (free cash flow to the firm)	—	-123.4	41.6	5.3	—
Capital Expenditure	—	112.7	75.5	31.2	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.